TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice - PubMed (original) (raw)

TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice

D Zhang et al. Nat Med. 2000 May.

Abstract

The transforming-growth-factor-beta-activated kinase TAK1 is a member of the mitogen-activated protein kinase kinase kinase family, which couples extracellular stimuli to gene transcription. The in vivo function of TAK1 is not understood. Here, we investigated the potential involvement of TAK1 in cardiac hypertrophy. In adult mouse myocardium, TAK1 kinase activity was upregulated 7 days after aortic banding, a mechanical load that induces hypertrophy and expression of transforming growth factor beta. An activating mutation of TAK1 expressed in myocardium of transgenic mice was sufficient to produce p38 mitogen-activated protein kinase phosphorylation in vivo, cardiac hypertrophy, interstitial fibrosis, severe myocardial dysfunction, 'fetal' gene induction, apoptosis and early lethality. Thus, TAK1 activity is induced as a delayed response to mechanical stress, and can suffice to elicit myocardial hypertrophy and fulminant heart failure.

PubMed Disclaimer

Cited by

Cardiac Hypertrophy: From Pathophysiological Mechanisms to Heart Failure Development.
Caturano A, Vetrano E, Galiero R, Salvatore T, Docimo G, Epifani R, Alfano M, Sardu C, Marfella R, Rinaldi L, Sasso FC. Caturano A, et al. Rev Cardiovasc Med. 2022 May 6;23(5):165. doi: 10.31083/j.rcm2305165. eCollection 2022 May. Rev Cardiovasc Med. 2022. PMID: 39077592 Free PMC article. Review.
Downregulation of Mitochondrial Fusion Protein Expression Affords Protection from Canonical Necroptosis in H9c2 Cardiomyoblasts.
Toda Y, Ong SB, Yano T, Kuno A, Kouzu H, Sato T, Ohwada W, Tatekoshi Y, Ogawa T, Shimizu M, Tanno M, Furuhashi M. Toda Y, et al. Int J Mol Sci. 2024 Mar 2;25(5):2905. doi: 10.3390/ijms25052905. Int J Mol Sci. 2024. PMID: 38474152 Free PMC article.
TAK1 Activation by NLRP3 Deficiency Confers Cardioprotection Against Pressure Overload-Induced Cardiomyocyte Pyroptosis and Hypertrophy.
Li X, You J, Dai F, Wang S, Yang FH, Wang X, Ding Z, Huang J, Chen L, Abudureyimu M, Tang H, Yang X, Xiang Y, Backx PH, Ren J, Ge J, Zou Y, Wu J. Li X, et al. JACC Basic Transl Sci. 2023 Aug 9;8(12):1555-1573. doi: 10.1016/j.jacbts.2023.05.008. eCollection 2023 Dec. JACC Basic Transl Sci. 2023. PMID: 38205342 Free PMC article.
Transforming growth factor-β and bone morphogenetic protein signaling pathways in pathological cardiac hypertrophy.
Wen J, Liu G, Liu M, Wang H, Wan Y, Yao Z, Gao N, Sun Y, Zhu L. Wen J, et al. Cell Cycle. 2023 Nov;22(21-22):2467-2484. doi: 10.1080/15384101.2023.2293595. Epub 2024 Jan 18. Cell Cycle. 2023. PMID: 38179789 Free PMC article. Review.
Guanxinning tablets improve myocardial hypertrophy by inhibiting the activation of MEK-ERK1/2 signaling pathway.
Zhang Y, Huang Y, Ma QX, Xu ST, Shen L, Xu YY, Hai-Ye T, Chen ML, Rong YL. Zhang Y, et al. J Appl Biomed. 2023 Sep;21(3):137-149. doi: 10.32725/jab.2023.014. Epub 2023 Sep 18. J Appl Biomed. 2023. PMID: 37747313

TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice - PubMed (original) (raw)